changed therapy. In the oral treatment group 32% of patients are adherent to their first-line treatment and 54% have changed treatment. Probabilistic-sensitivity-analyses demonstrated the robustness of the model regarding assumptions and input-parameters. CONCLUSIONS: A treatment switch to Paliperidone palmitate is a cost-effective alternative, improves treatment adherence and reduces health-care costs in the future and leads to higher quality-of-life.
OBJECTIVES:
To give a literature review and assess the health status utility and productivity of adult patients with attention-deficit/hyperactivity disorder (ADHD) focusing on measures with outstanding importance for health economic analysis. METHODS: PubMed was systematically reviewed for adult ADHD studies involving the EQ-5D and/or Work Productivity and Activity Impairment (WPAI) questionnaires. A cross sectional survey in an outpatient psychiatry centre was performed and the Clinical Global Impression scale (CGI-S) was used to categorize patients by severity. RESULTS: While several studies assessed the impact of ADHD in childhood only one (Patient 2011; 4(4) :247-57) dealt with EQ-5D in adult patients and none applied WPAI. In our survey, fortyfour patients (males 79.5%) were involved with mean (SD) age of 30.0 (9.9) years and disease duration of 7.6 (6.6) years. Thirty-three (75%) were singles, 9 (20.5%) married (20.5%), 2 (4.5%) divorced and 9 (20.5%) had children. Highest educational level was primary, secondary school and university at 5 (11.4%), 22 (50.0%) and 17 (38.7%) cases, respectively. Twenty-nine (65.9%) were taking medication for ADHD, seven (15.9%) needed accompanying person when travelling for health care. Injury requiring medical care occurred at 6 (13.6%) patients, 4 related to ADHD by self-report. Usual activities, pain/discomfort and anxiety/ depression were the most affected EQ-5D dimensions (moderate problem: 52.3%, 47.7%, 54.5%) and the EQ-5D score (mean 0.747, SD 0.280) was significantly lower than the age-matched population norm (pϽ0.05). Utility in mild (CGI-Sϭ3) and moderate (CGI-Sϭ4) health state was 0.799 and 0.706, respectively. Twenty-three (52.3%) patients were working, 17 (38.6%) were students and 4 (9.1%) unemployed. WPAI results were as follows, mean (SD): absenteeism 0.1 (0.3)%, presenteeism 33.0 (26.2)%, overall work impairment 16.9 (22.8)%, activity impairment 39.5 (28.7)%. CONCLUSIONS: Health status utility and productivity in adult ADHD is underexplored. Our study suggests that impaired everyday activities and preseenteism are considerable and deserve further research.
PMH36 TIME TRADE-OFF (TTO) ANALYSIS TO ELICIT HEALTH STATE UTILITIES RELATED TO LONG ACTING TREATMENTS IN SCHIZOPHRENIA
Jensen R 1 , Sommer KJ 2 , Søltoft F 2 , Schmidt A 3 , Nielsen AT 4 , Garg M 2 , Mønsted C 5 , Bøgelund M 5 1 Janssen EMEA, Birkerød, Denmark, 2 Janssen Cilag, Birkerød, Denmark, 3 Janssen Cilag, Sollentuna, Sweden, 4 University of Copenhagen, Frederiksberg C, Denmark, 5 Incentive Partners, Holte, Denmark OBJECTIVES: To assess preferences, using the time trade-off (TTO), regarding frequencies of having to go for a doctor's visit to receive pharmacological injections for the treatment of schizophrenia. METHODS: A survey was conducted in Sweden; respondents including 259 patients with a serious mental disorder, 263 relatives of individuals suffering from a serious mental disorder, and 528 people sampled from the general population were recruited for the purpose of this study. A time tradeoff (TTO) study design was used to elicit the utility of decreasing the frequency of necessary doctor visits. Average utilities were calculated for each health state for each respondent group. The marginal disutility of an additional yearly visit to the doctor was estimated using a standard OLS regression with an intercept. Bootstrapping was utilized to compute 95% confidence intervals around utilities and marginal disutilities. RESULTS: The marginal disutility of an additional doctor visit was found to be 0.0041 for patients, 0.0022 for relatives, 0.0017 for the general population and 0.0022 for an average respondent. For an average respondent across all groups, this corresponded to an additional utility of 0.031 between having to visit the doctor for an injection once a month versus every other week and 0.048 between having to visit the doctor for an injection once every 3 months versus every other week. CONCLUSIONS: The results are suggestive of a general trend of increased reported disutility for a higher number of doctor visits for an injection per year across all respondent groups.
PMH37 SYSTEMATIC REVIEW OF HEALTH STATE UTILITIES IN ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Zimovetz E 1 , Setyawan J 2 , Beard S 1 , Hodgkins P 2 1 RTI Health Solutions, Manchester, UK, 2 Shire Pharmaceuticals LLC, Wayne, PA, USA OBJECTIVES: To systematically identify and review published evidence on healthstate utility weights in paediatric and adolescent ADHD. METHODS: Utility weights were identified as part of a wider systematic review, which was performed to identify input parameter values for an economic model in ADHD. PubMed, EM-BASE, Cochrane National Health Service's Economic Evaluation Database, EconLit, and Health Economic Evaluations Database were searched from 1960 to May 2011. The review focused on articles reporting utility weights in ADHD by level of treatment response. RESULTS: A total of 1,648 unique titles and abstracts were retrieved; 1,630 records were excluded upon title (or abstract) review and 12 upon full-text review. The review included 6 studies reporting utilities by level of response, 2 of which further stratified utilities by treatment type. One study reported utilities for 4 health states ('normal', 'borderline to mildly ill', 'moderately to markedly ill', and 'severely ill'). One study used the EQ-5D instrument completed by parents; 2 assessed parents' preferences using standard gamble; 1 used statistical mapping (for responder and nonresponder states) and time trade-off (TTO) interviews and visual analogue scales (for 4 disease-severity health states); 1 calculated scores from other utility studies; and 1 did not report methods explicitly. Utilities for responders ranged between 0.98 and 0.80; utilities for non-responders ranged between 0.93 and 0.70. TTO-derived utilities for the 4 health states were rated by members of the general public and ranged from 0.839 ('normal') to 0.444 ('severely ill'). The review assessed the methodological compliance of each included study with NICE Reference Case. CONCLUSIONS: Our review identified utility estimates potentially suitable for use in ADHD economic evaluations. Appropriateness of these for inclusion in a particular analysis needs to be assessed in terms of the modelled heath states and the clinical outcomes used to define these. 
PMH38 ASSESSING DEPRESSIVE SYMPTOMS IN PRIMARY CARE: PSYCHOMETRICAL PROPERTIES OF THE SPANISH VERSION OF THE CLINICALLY USEFUL DEPRESSION OUTCOME SCALE

OBJECTIVES:
To validate the clinically useful depression outcome scale (CUDOS) for evaluating the severity of depressive symptoms in patients with major depressive disorder (MDD) attending a Primary Care Service. METHODS: An epidemiological, cross-sectional, multicentre study was conducted including adult patients diagnosed as MDD according to the DSM-IV TR during the last 3 months. The following instruments were applied: Primary Care Evaluation of Mental Disorders (PRIME-MD), Hamilton Rating Scale for Depression (HAMD-17), CUDOS, Social and Occupational Functioning Assessment Scale (SOFAS), SF-36 (Physical -PCS-and Mental -MCS-Component Summaries) and the Clinical global Impression for Severity of Illness (CGI-SI). CUDOS feasibility, internal consistency (Cronbach=s ␣), convergent validity (Spearman correlation with SOFAS, HAMD-17 and SF-36) and discriminant validity (differences in CUDOS values according to HAMD-17 classification of severity and the CGI-SI: Kruskal-Wallis and Mann-Whitney U -Bonferroni correction-) were evaluated. Finally, a cut-off score (Receiver Operation Curve-ROC-analysis) was calculated using the HAMD-17 as criterion (0-7ϭ remission). RESULTS: In total, 305 MDD patients with a mean age (SD) of 51.75 (15.53) years (30.5% males) were interviewed. According to the HAMD-17, 7.9% of patients were in remission, 29.8% suffered from mild depression, 22.0% moderate depression, 21.0% severe and 19.3% very severe. Mean(SD) time for completion was 4.47(2.4) minutes and floor or ceiling effects were found in less than 1% of patients. Cron-bach=s ␣ was high (0.877). Correlations with CUDOS were: -0.402(SOFAS), A340 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
